Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Hodgkin lymphoma
PET-2
PET-adapted strategy
TARC
advanced stage
biomarker
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
31
03
2020
revised:
24
06
2020
accepted:
25
06
2020
pubmed:
1
7
2020
medline:
3
11
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub-study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET-2 by commercially available ELISA test kits. The primary end-point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC-2 values were significantly higher in PET-2-positive patients compared to PET-2-negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4-year PFS significantly differed between patients with TARC-2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET-2-negative patients, elevated TARC-2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC-2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET-2-negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC-2 serum levels above 800 pg/mL suggest the need for a stringent follow-up in PET-2-negative patients, and the evaluation of new drugs in PET-2-positive, who will likely fail to respond to intensification with escalated BEACOPP.
Substances chimiques
Biomarkers, Tumor
0
CCL17 protein, human
0
Chemokine CCL17
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
501-508Subventions
Organisme : Michelangelo Foundation
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005;65(13):5516-5519.
Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008;140(5):527-536.
Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol. 1999;154(6):1685-1691.
Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and reed-Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer. 2002;98(4):567-572.
Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-2346.
Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol. 2002;13(Suppl 1):52-56.
Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012;97(3):410-415.
Jones K, Vari F, Keane C, et al. Serum CD 163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2012;19(3):731-742.
Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19(24):6812-6819.
Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013;88(2):113-115.
Guidetti A, Mazzocchi A, Miceli R, et al. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin lymphoma. Leuk Res. 2017;62:91-97.
Harrison SJ, Hsu AK, Neeson P, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55(5):1053-1060.
Farina L, Rezzonico F, Spina F, et al. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):1982-1988.
Plattel WJ, Visser L, Diepstra A, et al. Interim thymus and activation regulated chemokine versus interim 18F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020;190:40-44. https://doi.org/10.1111/bjh.16514.
Press OW, Li H, Schöder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016;34(17):2020-2027.
Stephens DM, Li H, Schoeder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma. Blood. 2019;134:1238-1246. https://doi.org/10.1182/blood.2019000719.
Johnson P, Federico M, Kikwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419-2429.
Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454-462.
Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20:202-215.
Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44:97-110. suppl 1.
Barrington SF, Johnson PWM. 18F-FDG PET/CT in lymphoma: has imaging-directed personalized medicine become a reality? J Nucl Med. 2017;58(10):1539-1544.
Aldin A, Umlauff L, Estcourt LJ, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9(9):1-146. https://doi.org/10.1002/14651858.CD012643.pub2.
His ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762-1765.
Cuccaro A, Annunziata S, Cupelli E, et al. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Med. 2016;5(3):398-406.
Sureda A, Connors JM, Younes A, et al. Serum sCD30 and TARC do not correlate with PET-based response assessment in patients with stage III or IV classical Hodgkin lymphoma: phase 3 Echelon-1 study of Brentuximab Vedotin plus chemotherapy vs chemotherapy alone. Hemasphere. 2018;2(suppl1):35-36. abstr P0159.
Radford J, Connors JM, Younes A, et al. Exploratory biomarker analysis in the ph 3 Echelon-1 study: worse outcome with ABVD in patients with elevated baseline levels of sCD30 and TARC. Hematol Oncol. 2019;37:290-291. suppl 2) (abstr.235.
Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413-2425.
Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica. 2019;104(4):648-652.